SCHEMBL3828447

SCHEMBL3828447

CCCC(Br)C(=O)C(=O)OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZDHHC7 Q9NXF8 1/20 0.40
ALDH1A1 P00352 5/20 0.37
TRPA1 O75762 1/20 0.37
NPSR1 Q6W5P4 2/20 0.36
GLO1 Q04760 1/20 0.36
LMNA P02545 2/20 0.36
HSD17B10 Q99714 1/20 0.36
TSHR P16473 1/20 0.35
LCK P06239 1/20 0.35
PPARD Q03181 1/20 0.35
ZDHHC20 Q5W0Z9 1/20 0.35
ZDHHC2 Q9UIJ5 1/20 0.35
MAPT P10636 4/20 0.35
ALOX15 P16050 1/20 0.34
MGAM O43451 1/20 0.34
GAA P10253 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34
SOAT1 P35610 1/20 0.34
EGLN1 Q9GZT9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6337398 0.88 ZDHHC7 (0.50) ZDHHC7ALDH1A1TRPA1NPSR1GLO1
SCHEMBL26984770 0.86 ALDH1A1 (0.36) ZDHHC7ALDH1A1TRPA1NPSR1GLO1
SCHEMBL112412 0.83 ALDH1A1 (0.40) ZDHHC7ALDH1A1TRPA1NPSR1GLO1
SCHEMBL2823450 0.82 ALDH1A1 (0.45) ZDHHC7ALDH1A1NPSR1HSD17B10TSHR
SCHEMBL11955306 0.81 ZDHHC7 (0.40) ZDHHC7ALDH1A1TRPA1NPSR1GLO1
SCHEMBL594084 0.81 ZDHHC7 (0.40) ZDHHC7ALDH1A1TRPA1NPSR1GLO1
SCHEMBL1732719 0.80 ZDHHC7 (0.48) ZDHHC7ALDH1A1TRPA1NPSR1LMNA
SCHEMBL304907 0.80 ZDHHC7 (0.48) ZDHHC7ALDH1A1TRPA1NPSR1LMNA
SCHEMBL1732564 0.80 ZDHHC7 (0.48) ZDHHC7ALDH1A1TRPA1NPSR1LMNA
SCHEMBL11491094 0.80 KYAT1 (0.41) ZDHHC7ALDH1A1HSD17B10TSHRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151402-A1 THIAZOLE TRPML1 AGONISTS AND USES THEREOF LIBRA THERAPEUTICS, INC. (US) 2025-07-17 WO disclosed
CN-105658648-B Deoxycytidine kinase inhibitors 加利福尼亚大学董事会 2020-03-17 CN disclosed
US-9688673-B2 Deoxycytidine kinase binding compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-06-27 US disclosed
US-9688673-B2 Deoxycytidine kinase binding compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-06-27 US disclosed
US-9688673-B2 Deoxycytidine kinase binding compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-06-27 US disclosed
US-20130336883-A1 DEOXYCYTIDINE KINASE BINDING COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-12-19 US disclosed
WO-2012122368-A1 DEOXYCYTIDINE KINASE BINDING COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-09-13 WO disclosed
WO-2012122368-A1 DEOXYCYTIDINE KINASE BINDING COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-09-13 WO disclosed
US-20090312310-A1 Imidazothiazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-12-17 US disclosed
US-20090312310-A1 Imidazothiazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-12-17 US disclosed
US-6960601-B2 Preparation and use of imidazole derivatives for treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2005-11-01 US disclosed
WO-2005099705-A2 PREPARATION OF IMIDAZOLE DERIVATIVES AND METHODS OF USE BAYER PHARMACEUTICALS CORPORATION (US) 2005-10-27 WO disclosed
US-6936617-B2 Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands NEUROGEN CORPORATION (US) 2005-08-30 US disclosed
CN-1599724-A Imidazole-4-carboxamide derivatives, their preparation and use in the treatment of obesity BAYER PHARMACEUTICALS CORPORAT (US) 2005-03-23 CN disclosed
EP-1432691-A1 IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP disclosed
EP-1406906-A1 HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2004-04-14 EP disclosed
US-20040063691-A1 Preparation and use of imidazole derivatives for treatment of obesity BAYER PHARMACEUTICALS CORPORATION 2004-04-01 US disclosed
US-20030207885-A1 Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands NEUROGEN CORPORATION 2003-11-06 US disclosed
WO-2003040107-A1 IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY BAYER PHARMACEUTICALS CORPORATION (US) 2003-05-15 WO disclosed
WO-2003006471-A1 HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312310-A1 Imidazothiazole derivatives TP53, MDM2, TP53BP1 ZDHHC7 2948/4885ALDH1A1 1990/4885TRPA1 3215/4885
US-20040063691-A1 Preparation and use of imidazole derivatives for treatment of obesity GPR119, GIPR, PGC ZDHHC7 1764/4885ALDH1A1 2202/4885TRPA1 1399/4885
US-20030207885-A1 Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands GABRA5, GABRA2, GABBR1 ZDHHC7 2986/4885ALDH1A1 553/4885TRPA1 753/4885
US-20130336883-A1 DEOXYCYTIDINE KINASE BINDING COMPOUNDS DCK, DTYMK, DCTD ZDHHC7 2045/4885ALDH1A1 3100/4885TRPA1 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.